Antiviral drug joins fight against aggressive lung cancer
NCT ID NCT04696575
Summary
This study is testing whether adding an oral antiviral drug called lamivudine to the standard first-line treatment (chemotherapy plus immunotherapy) can help control extensive stage small cell lung cancer for a longer period. The goal is to see if lamivudine can reduce the cancer's ability to become resistant to treatment. About 28 adults with this specific type of advanced lung cancer will receive the combination to see if it improves how long they live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.